+41 91 682 20 40 info@elixi-int.com

Elebrato Ellipta (fluticasone furoate / umeclidinium / vilanterol): new medicine authorised for the treatment of chronic obstructive pulmonary disease (COPD)

Elebrato Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Elebrato Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines called corticosteroids and long-acting beta-2 agonists. Corticosteroids reduce inflammation in the airways and lungs, and long-acting beta-2 agonists widen the airways.

Elebrato Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.

Elebrato Ellipta contains three active substances, which work in different ways to widen the airways and improve breathing in COPD.

Fluticasone furoate is a corticosteroid. It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors (targets) in various types of immune cells. This reduces the release of substances involved in the inflammation process, such as histamine, thereby reducing inflammation and helping to keep the airways clear and allowing the patient to breathe more easily.

Umeclidinium bromide is a muscarinic receptor antagonist. It works by blocking muscarinic receptors, which are involved in the contraction of muscles. When umeclidinium bromide is inhaled, it causes the muscles of the airways to relax.

Vilanterol is a long-acting beta-2 agonist. It works by attaching to beta-2 receptors in some types of muscle cells. When inhaled, vilanterol activates the beta-2 receptors in the airways. This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.

The European Medicines Agency decided that Elebrato Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.

The Agency concluded that Elebrato Ellipta improves lung function as well as the quality of life of patients with moderate to severe COPD.

Regarding the safety profile of the medicine, the most frequent side effects reported with Elebrato Ellipta were similar to those with the individual active substances of the medicine and are well known.

For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at info@elixi-int.com

We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.